Markets:

Overview

News

Currencies

International

Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

5.210 -0.100 (-1.88%)

Streaming Delayed Price Updated: 10:22 AM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Taysha Gene Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Taysha Gene Therapies Inc (NASDAQ:TSHA) Stock Slumps on Q3 Revenue Miss Despite Key Regulatory Win for TSHA-102 ↗

November 04, 2025

Taysha Gene Therapies stock fell after Q3 results, with a revenue miss overshadowing positive FDA Breakthrough Therapy designation for its Rett syndrome drug.

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

October 20, 2025

Via Benzinga

Why Is Taysha Gene Therapies Stock Falling Friday? ↗

October 17, 2025

Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial.

Via Benzinga

Taysha Gene Therapies Stock Soars To 3-Year High After FDA Boost — Wall Street Calls Rett Drug ‘Derisked’ And Ahead Of Rivals ↗

October 03, 2025

Taysha shares jumped after analysts at Baird, H.C. Wainwright, and Needham turned bullish, citing FDA alignment and an expedited approval path for its Rett syndrome therapy.

Via Stocktwits

What's Next: Taysha Gene Therapies's Earnings Preview ↗

August 11, 2025

Via Benzinga

Where Taysha Gene Therapies Stands With Analysts ↗

June 02, 2025

Via Benzinga

Healthcare Sector Shines Amidst Market Turbulence, Bolstering S&P 500 Resilience

October 02, 2025

On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's...

Via MarketMinute

Demystifying Taysha Gene Therapies: Insights From 6 Analyst Reviews ↗

October 02, 2025

Via Benzinga

Discover the most active stocks in Thursday's session. ↗

October 02, 2025

These stocks are making the most noise in today's session. Stay tuned for the latest updates!

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 02, 2025

Via Benzinga

Here are the top movers in Thursday's session. ↗

October 02, 2025

Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday ↗

October 02, 2025

U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday.

Via Benzinga

Topics Stocks

Taysha Gene Therapies Stock Soars After FDA Grants Breakthrough Therapy Designation To Gene Therapy ↗

October 02, 2025

Taysha also announced that it has finalized alignment with the FDA on the protocol for the trial intended to support its application for approval of TSHA-102.

Via Stocktwits

Which stocks are gapping on Thursday? ↗

October 02, 2025

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

Top 2 Health Care Stocks That May Keep You Up At Night This Month ↗

October 02, 2025

Via Benzinga

What's Driving the Market Sentiment Around Taysha Gene Therapies? ↗

September 18, 2025

Via Benzinga

Is Taysha Gene Therapies Gaining or Losing Market Support? ↗

August 25, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through 11 Analysts ↗

August 13, 2025

Via Benzinga

Beyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies Stock ↗

July 01, 2025

Via Benzinga

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data ↗

June 03, 2025

Canaccord Genuity raised its price target on Taysha Gene Therapies to $11 from $9, citing improved clinical data and increased confidence in the company’s TSHA-102 program.

Via Stocktwits

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday? ↗

May 29, 2025

Taysha shared the TSHA-102 trial plan after FDA alignment and reported 100% milestone gains with no serious adverse events in Rett syndrome patients.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 29, 2025

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 28, 2025

Via Benzinga

Get insights into the top gainers and losers of Wednesday's after-hours session. ↗

May 28, 2025

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

Expert Outlook: Taysha Gene Therapies Through The Eyes Of 6 Analysts ↗

May 16, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 15, 2025

Via Benzinga

Earnings Scheduled For May 15, 2025 ↗

May 15, 2025

Via Benzinga

Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗

May 07, 2025

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.